

Values expressed are % susceptible by Broth Microdilution MIC *

Gram Negative Bacilli ***

	No. of Isolates	Penicillins		Cephalosporins					Aminoglyc's			Lactams		Others		Urines Only	
		Ampicillin (\$)	Piper/Tazobactam (\$\$\$)	Cefazolin (\$)	Cefuroxime (IV) (\$\$)	Ceftriaxone (\$\$\$)	Ceftazidime (\$\$\$)	Cefepime (\$\$\$)	Amikacin (\$\$)	Gentamicin (\$)	Tobramycin (\$\$)	Aztreonam (\$\$\$)	Meropenem (\$\$\$)	Ciprofloxacin (\$\$\$)	Co-trimoxazole (\$)	1st generation Cepheims	Nitrofurantoin (\$)
<i>Achromobacter xylosoxidans</i>	15		80				27	13	0	0	0	0	80	13	73		
<i>Acinetobacter baumannii</i>	14						86	64	100	100	100	21	100	100	93		
<i>Citrobacter freundii</i>	14			7	64	64	64			86	93			100	50		
<i>Enterobacter aerogenes</i>	19		64	5	47	56	56	100	100	100	100	70	100	95	100		6
<i>Enterobacter cloacae</i>	66		78	3	33	74	74	100	98	97	97	70	100	100	85	0	39
<i>Escherichia coli</i>	362	50	100	92	93	99	99	99	100	96	96	98	100	94	72	52	97
<i>Klebsiella oxytoca</i>	34	6	94	77	94	94	94	94	100	91	91	88	100	100	88	94	95
<i>Klebsiella pneumoniae</i>	52	2	96	94	89	96	94	96	100	98	98	96	100	100	75	92	23
<i>Morganella morganii</i>	14	0		0	14	100	100			93	100			86	86	0	0
<i>Proteus mirabilis</i>	56	81	100	95	100	100	100	100	100	98	100	100	100	100	84	97	0
<i>Pseudomonas aeruginosa</i>	86		97				90	91	95	86	92	84	97	92			
<i>Pseudomonas aeruginosa</i> (CF-mucoid) **	93		Pip 89	Tic 87	Imp 90		90	88			83	84	98	75			
<i>Pseudomonas aeruginosa</i> (CF-non-mucoid) **	108		Pip 86	Tic 81	Imp 81		86	84			62	80	86	64			
<i>Serratia marcescens</i>	31	8	85	0	0	87	90	93	93	87	81	89	100	97	90		
<i>Stenotrophomonas maltophilia</i>	52		Tic/Clav 41						Levo 81					19	96		

* All data based on first isolate per patient only

** Cystic fibrosis patient isolates tested by disk diffusion

*** Not all isolates tested against every antibiotic.

Pip = Piperacillin; Tic = Ticarcillin; Imp = Imipenem;
Tic/Clav = Ticarcillin/Clavulanate; Levo = Levofloxacin

Gram Positive Cocci

Values expressed are % susceptible*

	Number of Isolates	Beta-Lactams						Others								
		Oxacillin/Nafticillin (\$)		Penicillin or Ampicillin (\$)		1st Generation cepheems	Cefuroxime (\$\$)	Ceftriaxone** (\$\$\$)	Meropenem (\$\$\$)	Gentamicin (\$)	Ciprofloxacin (\$\$\$)	Clindamycin ***(\$)	Erythromycin (\$)	Nitrofurantoin - urine (\$)	Co-trimoxazole (\$)	Vancomycin (\$)
		%S	%I	%R												
Staphylococcus aureus	328	82	10			82				95	78	52		100	100	
MRSA only	64	0	0			0				86	40	11		100	100	
Staphylococcus epidermidis	11	18	0			18				46	46	27		55	100	
Staphylococcus sp., Coagulase-negative	229	25	8			25				50	48	22		69	100	
Enterococcus faecium	20		20	0	80										77	
Enterococcus faecalis	38		100	0	0										100	
Enterococcus sp. (not identified to species)	121		99	0	1					97			100		100	
Streptococcus group B (vag/anal screen)	223		100	0	0						87	82				
viridans group streptococci	31		32	52	16			77			92	45			100	
Streptococcus pneumoniae	33		67	18	15		82	88	82		81	79		70	100	

Drug cost: Low (\$); Moderate (\$\$);
High (\$\$\$)

*All data based on first isolate per patient only

**Ceftriaxone uses the meningitis interpretive criteria (more conservative)

***Testing for inducible clindamycin resistance performed by M.D. request only

Candida (LPCH isolates only)

Percent Susceptible By Broth Microdilution (YeastOne, Trek Diagnostics)	No. Tested	Amphotericin B	Fluconazole	Itraconazole	Voriconazole (a)
Candida albicans	18	100	100	100	100
Candida glabrata	4	100	75	50	50
Candida parapsilosis	7	100	100	100	100
Other Candida species	4	100	(b)	100	100

(a) Consult Peds ID if Voriconazole being considered for treatment. Not all isolates tested vs. Voriconazole.

(b) Species other than C. krusei are 100% susceptible; C. krusei is intrinsically resistant to fluconazole.

Haemophilus influenzae notes:

For infections with beta-lactamase producing *H. influenzae*: cefuroxime, cefotaxime, trimethoprim/sulfamethoxazole, amoxicillin/clavulanate, or azithromycin is recommended.

Cefotaxime or ceftriaxone is the drug of choice for CNS infections. At LPCH, 67% of *H. influenzae* are ampicillin susceptible.



Lucile Packard Children's Hospital
STANFORD UNIVERSITY MEDICAL CENTER

STANFORD UNIVERSITY
MEDICAL CENTER

CLINICAL MICROBIOLOGY
LABORATORY

INTEGRATED INFECTIOUS
DISEASE PROGRAM

KATHLEEN M. GUTIERREZ, M.D.,
CHAIRPERSON

HOSPITAL ANTIBIOGRAM 2005
(BASED ON 2004 ISOLATES)